Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.684453
Title: Investigating the anti-inflammatory activity of a fragment of Chaperonin 60.1 derived from Mycobacterium tuberculosis
Author: Man, Francis Alexandre Wei Ming
ISNI:       0000 0004 5921 314X
Awarding Body: King's College London
Current Institution: King's College London (University of London)
Date of Award: 2016
Availability of Full Text:
Access through EThOS:
Access through Institution:
Abstract:
Chaperonin 60.1 (Cpn60.1) from Mycobacterium tuberculosis is a protein that has evolved from the traditional role of chaperone in protein folding to a role in extracellular signalling. While non-essential to the growth and survival of the bacteria, Cpn60.1 is essential to the formation of granuloma in tuberculosis [150]. Cpn60.1 has been shown to induce cytokine production in human monocytes [201], but also to prevent leukocyte migration in murine models of allergic lung inflammation [300]. Peptide 4, a fragment of Cpn60.1, has been shown to be responsible for the cytokineinducing activity of Cpn60.1 in monocytes [149] and has been shown in our laboratory to prevent leukocyte migration in models of allergic and non-allergic inflammation. We believe that Peptide 4 would be an interesting lead compound or drug candidate for the treatment of diseases in which leukocyte infiltration plays a major role, such as chronic obstructive pulmonary disease (COPD) or acute respiratory distress syndrome (ARDS). However, most of the knowledge regarding Peptide 4 originates from in vivo experiments and little is known about its mechanism of action. In addition, due to the size and nature of Peptide 4, there is potential for improvement in its drug-likeness while retaining its anti-inflammatory activity. The principal objective of this thesis was to develop in vitro screening assays for shorter fragments of the biologically active Peptide 4, as a preliminary step in developing a novel anti-inflammatory drug candidate. A number of functions of human neutrophils and mouse bone marrow cells were explored, such as adhesion molecule expression, cytoskeleton reorganisation, chemotaxis, adhesion to extracellular matrix proteins, platelet-leukocyte aggregate formation, and granule release. These assays were performed on isolated cells and whole blood. Because in vivo experiments revealed an effect of Peptide 4 on the expression of endothelial adhesion molecules and circulating pro-inflammatory cytokines, the peptide was also assayed in cultured human endothelial cells. Adhesion molecule expression was measured by flow cytometry and immuno-fluorescence microscopy. Cytokine release was measured by ELISA. Labelled peptides were used in attempts to observe the binding to cells. In each case, the focus was on finding an assay that would be convenient for screening purposes and relevant to the intended use of the compound as a drug for the treatment of human diseases. In addition, solid-phase synthesis of peptides derived from Peptide 4, including scrambled and fluorescent derivatives, was performed. Most synthesised peptides were tested in vivo for early structure-activity relationship studies. Some of the peptides contained fluorescent labels or affinity tags for imaging purposes. Some peptides were analysed by circular dichroism spectroscopy to obtain information about their secondary structure and behaviour in different environments. Several assays were developed in murine and human leukocytes. The results showed that Peptide 4 did not affect selectin or integrin expression, migration toward chemoattractants, adhesion to bronectin or endothelial cells, cell polarisation or the formation of platelet-leukocyte aggregates. Similarly, Peptide 4 did not affect the expression of adhesion molecules or the release of IL-6 and IL-8 by HUVECs. Altogether, the results suggested the effect of Peptide 4 was not directly mediated by neutrophils or endothelial cells. Experiments with fluorescent peptides were inconclusive, as consistent binding to the cells could not be achieved. In vivo testing of synthetic derivatives of Peptide 4 showed that a free N-terminus was important for biological activity, and that the lysine sidechain could be used as an anchor point for functional groups such as biotin or fluorescent dyes. In vivo studies also pointed towards an increased release of monocyte-attracting cytokines, and it was demonstrated that lung-resident phagocytes are essential to the biological activity of Peptide 4.
Supervisor: Page, Clive Peter ; Bansal, Sukhvinder Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.684453  DOI: Not available
Share: